Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_assertion description "[This model showed that: (i) the combination of five genetic alterations (CDK4, hTERT, sh-p53, KRAS(V12), and c-MYC) is sufficient for full tumorigenic conversion of HBECs; (ii) genetically identical clones of transformed HBECs exhibit pronounced differences in tumor growth, histology, and differentiation; (iii) HBECs from different individuals vary in their sensitivity to transformation by these oncogenic manipulations; (iv) high levels of KRAS(V12) are required for full malignant transformation of HBECs, however, prior loss of p53 function is required to prevent oncogene-induced senescence; (v) overexpression of c-MYC greatly enhances malignancy but only in the context of sh-p53+KRAS(V12); (vi) growth of parental HBECs in serum-containing medium induces differentiation, whereas growth of oncogenically manipulated HBECs in serum increases in vivo tumorigenicity, decreases tumor latency, produces more undifferentiated tumors, and induces epithelial-to-mesenchymal transition (EMT); (vii) oncogenic transformation of HBECs leads to increased sensitivity to standard chemotherapy doublets; (viii) an mRNA signature derived by comparing tumorigenic versus nontumorigenic clones was predictive of outcome in patients with lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_assertion evidence source_evidence_literature NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_assertion SIO_000772 23449933 NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_assertion wasDerivedFrom befree-2016 NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_assertion wasGeneratedBy ECO_0000203 NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.
- befree-2016 importedOn "2016-02-19" NP1056858.RA-opCcR43ibM1RVLYob4N6kn4jAx-y6xF46IDC6E1gSo130_provenance.